Arcturus Therapeutics (NASDAQ: ARCT) revenue
Arcturus Therapeutics reported revenue of $82.0m for fiscal 2025, 46.1% less than in fiscal 2024 ($152.3m). Since fiscal 2018 its revenue has grown by 420.7%, an average growth of 26.6% a year.
Arcturus Therapeutics's revenue has fallen for 3 years in a row, and its best year of the last 8 was fiscal 2022. The biggest drop was in fiscal 2020, −54.1%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $82.0m | −46.1% | −$76.3m | −93.0% |
| 2024 | $152.3m | −8.7% | −$95.7m | −62.8% |
| 2023 | $166.8m | −19.0% | −$78.2m | −46.9% |
| 2022 | $206.0m | +1,566.8% | $12.2m | 5.9% |
| 2021 | $12.4m | +29.6% | −$202.9m | −1,641.3% |
| 2020 | $9.5m | −54.1% | −$71.5m | −749.8% |
| 2019 | $20.8m | +32.0% | −$25.5m | −122.7% |
| 2018 | $15.8m | — | −$21.8m | −138.5% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Arcturus Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Arcturus Therapeutics ranks 299th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Arcturus Therapeutics, −46.1%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 297th | Nurix Therapeutics | $84.0m | 54.0% |
| 298th | Iradimed | $83.8m | 14.4% |
| 299th | Arcturus Therapeutics | $82.0m | −46.1% |
| 300th | MeiraGTx | $81.4m | 144.6% |
| 301st | ADC Therapeutics | $81.4m | 14.9% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Arcturus Therapeutics
- How much revenue did Arcturus Therapeutics make in fiscal 2025?
- Arcturus Therapeutics reported revenue of $82.0m for fiscal 2025, compared with $152.3m in fiscal 2024.
- How much has the revenue of Arcturus Therapeutics grown?
- Between fiscal 2018 and fiscal 2025 it went from $15.8m to $82.0m: 420.7% more, an average growth of 26.6% a year.
- What was the best year for revenue at Arcturus Therapeutics?
- Of its last 8 fiscal years, fiscal 2022, with $206.0m.
- Where does Arcturus Therapeutics rank in its sector by revenue?
- It ranks 299th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Arcturus Therapeutics come from?
- From the annual report (Form 10-K) that Arcturus Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Arcturus Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018. More on Arcturus Therapeutics: the Arcturus Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.